Clinical trial
A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model
NCT02094365 is registered in ClinicalTrials.gov with Alios Biopharma Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model
- Lead sponsor
- Alios Biopharma Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2014
- Completion date
- July 31, 2014
- Enrollment
- 62 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.